Questions about horse spleen ferritin crossing the blood brain barrier via mouse transferrin receptor 1
- 737 Downloads
Ferritin, an iron storage protein naturally occurring in the body, has emerged as a promising nanocarrier thanks to its unique architecture, excellent biocompatibility, and ability to self-assemble/disassemble (Fan et al., 2013). More specifically, the finding that human H-ferritin intrinsically targets tumor cells via binding to its receptor transferrin receptor 1 (TfR1) (Li et al., 2010; Fan et al., 2012; Liang et al., 2014; Zhao et al., 2016) inspired research into using ferritins for tumor target therapy.
Recently, a paper published in Molecular Pharmaceutics showed that horse spleen ferritin (HosFn) binds to and crosses the mouse BBB because of binding to mouse TfR1 (Chen et al., 2017), which raises great concerns to us.
To the best of our knowledge, HosFn lacks the ability to cross the mouse BBB, due to its lack of binding to mouse TfR1. Below we briefly describe others’ and our own evidence supporting such a conclusion.
Firstly, in our own experiments, we failed to detect any specific binding sites for HosFn on mouse BBB endothelial bEnd.3 cells.
In our experiments, the pre-incubation of bEnd.3 cells with excess amount (up to 100-fold mole excess) of unlabeled HosFn exhibited little effect on the binding of FITC-labeled HosFn to these cells (Fig. 1D). These results suggest that no specific binding sites for HosFn were present on bEnd.3 cells, which further confirmed that HosFn does not bind to mouse TfR1.
Secondly, the conclusion that HosFn cannot bind to and cross the BBB in mice was also drawn by Connor and colleagues (Fisher et al., 2007). The receptor of HosFn was reported to be the mouse L-ferritin receptor—mouse Scara 5 by different groups (Sun et al., 2011; Mendes-Jorge et al., 2014; Conti et al., 2016), which is also consistent with the fact that nearly 92% (22/24) composition of HosFn is L subunits (Harrison, 1986; Sun et al., 2011), and HosFn is typically regarded as L-ferritin in most previous research (Sun et al., 2011; Mendes-Jorge et al., 2014; Geninatti Crich et al., 2015; Conti et al., 2016).
Taken together, the conclusions of Chen et al.’s work need to be reconsidered, as they are misleading at best. Here, we provide more information about ferritins and their receptors. Importantly, we hope that this commentary will clarify the precise nature of the interactions of ferritins with their receptors.
To date, several ferritin receptors have been identified (Fan et al., 2013; Heger et al., 2014; Belletti et al., 2017). Although ferritins are highly conserved in various species, their receptors could be very different, e.g., the receptor of human H-ferritin is TfR1, while that of mouse H-ferritin is TIM-2. Thus, we cannot infer that different ferritin receptors function similarly. As a matter of fact, ferritins from different species do play contrasting roles beyond iron storage. We hope to point out here that when employing ferritin as nanocarriers to develop anti-disease system, people must clearly recognize which ferritin and the corresponding receptor are suitable for their purpose. When HosFn is chosen, its corresponding cross-interactive receptor is Scara 5 in mouse. Other suitable receptors for this purpose are yet to be determined.
Compliance with Ethics Guidelines
Kelong Fan, Meng Zhou, and Xiyun Yan declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
This article does not contain any studies with human or animal subjects performed by any of the authors.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.